TITLE

HCV-Infected ESRD Patients at Increased Risk of Death

PUB. DATE
March 1999
SOURCE
Kidney;Mar/Apr99, Vol. 8 Issue 2, p72
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Presents an abstract of the study 'Risk of death among chronic dialysis patients infected with hepatitis C virus,' by C.O. Stehman-Breen, S. Emerson, D. Gretch, et al.
ACCESSION #
5770577

 

Related Articles

  • Occult hepatitis C virus infection in Iranian hemodialysis patients. Eslamifar, Ali; Ramezani, Amitis; Ehteram, Hassan; Razeghi, Effat; Ahmadi, Farrokhlagha; Amini, Manouchehr; Banifazl, Mohammad; Etemadi, Gelavizh; Keyvani, Hossein; Bavand, Anahita; Aghakhani, Arezoo // Journal of Nephropathology;Oct2015, Vol. 4 Issue 4, p116 

    Background: Occult hepatitis C virus (HCV) infection is defined as the presence of HCVRNA in liver or peripheral blood mononuclear cells (PBMCs) in the absence of detectable hepatitis C antibody (anti-HCV) or HCV-RNA in the serum. Low concentrations of HCVRNA may be detected in PBMCs of...

  • Recent Advances on Hepatitis C Virus in Dialysis Population. Fabrizi, Fabrizio; Messa, Piergiorgio; Martin, Paul // Kidney & Blood Pressure Research;Nov2014, Vol. 39 Issue 4, p260 

    Hepatitis C virus (HCV) infection remains common among patients undergoing regular dialysis and good evidence supports the detrimental role of HCV on survival in patients undergoing maintenance dialysis. According to an updated meta-analysis of clinical studies (n=15; 195,370 unique patients on...

  • Cost of interferon-alfa for chronic hepatitis C. Sadovsky, Richard // American Family Physician;6/1/1998, Vol. 57 Issue 11, p2824 

    Reports on the annual mortality rate of Americans who have hepatitis C virus infection with reference to the amount of persons who develop this infection. How hepatitis C can be considered; Effective use of the treatment with interferon-alfa; Circumstances surrounding the extension treatment.

  • Hepatitis C virus in hemodialysis patients. Espinosa, Mario; Martin-Malo, Alejandro; Aljama, Pedro; Rampino, Teresa; Canton, Antonio Dal // Kidney International;Jul2000, Vol. 58 Issue 1, p462 

    Presents a letter commenting on the infection characteristics of hepatitis C virus (HCV) in hemodialysis (HD) patients. Capability of the hepatocyte growth factor serum levels of attenuating liver damage caused by HCV; Association of anti-HCV with higher risk of mortality; Differences on the...

  • Prevalence and risk factors of hepatitis B and C viruses among haemodialysis patients in Gaza strip, Palestine. El-Ottol, Abed El-kader Y.; Elmanama, Abdelraouf A.; Ayesh, Basim M. // Virology Journal;2010, Vol. 7, p210 

    Background: The prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) and its associated risk factors among haemodialysis (HD) patients in Gaza strip was investigated using serological and molecular techniques. Results: The overall prevalence of HBV among the four HD centers was...

  • Clinical significance of alanine aminotransferase levels and the effect of ursodeoxycholic acid in hemodialysis patients with chronic hepatitis C. Nishida, Chika; Uto, Hirofumi; Oketani, Makoto; Tokunaga, Koki; Nosaki, Tsuyoshi; Fukumoto, Mayumi; Oku, Manei; Sogabe, Atsushi; Moriuchi, Akihiro; Ido, Akio; Tsubouchi, Hirohito // Journal of Gastroenterology;Mar2010, Vol. 45 Issue 3, p326 

    The natural history of hepatitis C virus (HCV) carriers and the effect of ursodeoxycholic acid (UDCA) have not been fully elucidated among hemodialysis (HD) patients. Eighty-four anti-HCV antibody- and HCV RNA-positive and 154 anti-HCV antibody-negative HD patients who were retrospectively...

  • Undiagnosed hepatitis C virus infection in hemodialysis patients: Value of HCV RNA and liver enzyme levels. Caramelo, Carlos; Bartolomé, Javier; Albalate, Marta; de Sequera, Patricia; Navas, Sonia; Bermejillo, Teresa; Oliva, Horacio; Marriott, Eduardo; Ortiz, Alberto; Tuñón, Carmen Ruiz; Casado, Santos; Carreño, Vicente // Kidney International;Dec1996, Vol. 50 Issue 6, p2027 

    At present, routine screening for hepatitis C virus (HCV) infection is based on the detection of antiviral antibodies. Underdiagnosis of HCV infection by using HCV antibody tests, however, still occurs. Additional diagnostic means are provided by the polymerase chain reaction (PCR). The...

  • Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection. Suda, Goki; Hasebe, Chitomi; Abe, Masami; Kurosaki, Masayuki; Itakura, Jun; Izumi, Namiki; Uchida, Yoshihito; Mochida, Satoshi; Haga, Hiroaki; Ueno, Yoshiyuki; Abe, Kazumichi; Takahashi, Atsushi; Ohira, Hiromasa; Tsukuda, Yoko; Furuya, Ken; Baba, Masaru; Yamamoto, Yoshiya; Kobayashi, Tomoe; Inoue, Jun; Terasita, Katsumi // Journal of Gastroenterology;Jul2019, Vol. 54 Issue 7, p641 

    Background: Until recently, interferon-free anti-hepatitis C virus (HCV) therapy for genotype 2 (GT2) HCV-infected hemodialysis patients was an unfulfilled medical need. Recent clinical trials of glecaprevir and pibrentasvir (G/P) for hemodialysis patients showed high efficacy and...

  • Rising burden of Hepatitis C Virus in hemodialysis patients.  // Virology Journal;2011, Vol. 8 Issue 1, p438 

    The article offers information on the study conducted by the authors related to the rising burden of hepatitis C virus (HCV) in hemodialysis (HD) patients. It states that polymerase chain reaction was performed for HCV RNA detection and genotyping in 384 HD patients. The data obtained was...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics